Healionics
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$1.7m | Series A | ||
* | $2.6m | Series B | |
N/A | $200k | Seed | |
N/A | $50.0k | Debt | |
N/A | Convertible | ||
$4.5m | Convertible | ||
N/A | N/A | Series A | |
$4.7m | Late VC | ||
* | $5.5m | Late VC | |
Total Funding | AUD29.7m |
Related Content
Recent News about Healionics
EditHealionics is a pioneering company in the medical technology sector, specializing in advanced biomaterial solutions designed to improve dialysis access and reduce infection risks for patients with kidney failure. Operating primarily in the healthcare and medical device market, Healionics collaborates closely with leading institutions such as the University of Washington, Northwest Kidney Centers, and the Kidney Research Institute. The company's core product, STARgraft, is a synthetic vascular graft that offers superior performance in terms of durability and infection resistance compared to traditional options. Healionics generates revenue through the sale of its proprietary medical devices to healthcare providers and institutions that manage dialysis treatments. By focusing on innovation and leveraging its strong network of medical advisors and scientific experts, Healionics aims to address critical challenges in dialysis treatment and improve patient outcomes.
Keywords: biomaterials, dialysis, vascular graft, infection prevention, kidney failure, medical devices, healthcare innovation, STARgraft, patient outcomes, Seattle.